Atea Pharmaceuticals, Inc. (AVIR) Financial Statements
Atea Pharmaceuticals, Inc. (AVIR) reported trailing twelve-month revenue of $351.4M (up 0.0% year on year) and net income of -$165.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$152.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVIRAtea Pharmaceuticals, Inc.Follow AVIR — free
—
Price chart with a free account
- Market cap
- 324.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Research & development | 38.0 | 167.2 | 81.9 | 114.2 | 144.1 | 148.0 | 155.4 | |
| Operating income | -11.0 | 138.4 | -130.7 | -164.2 | -193.0 | -180.9 | -183.6 | |
| Pre-tax income | -10.9 | 138.6 | -119.5 | -134.9 | -167.5 | -164.5 | -171.8 | |
| Income tax | — | 17.4 | -3.6 | 1.0 | 0.9 | -6.2 | -6.5 | |
| Net income | -10.9 | 121.2 | -115.9 | -136.0 | -168.4 | -158.3 | -165.3 | |
| Diluted EPS ($) | -0.51 | 1.37 | -1.39 | -1.63 | -2.00 | -1.94 | -2.08 | |
| Diluted shares (mn) | — | 88.2 | 83.2 | 83.4 | 84.3 | 81.5 | — |
USD millions · SEC XBRL
Atea Pharmaceuticals, Inc. — questions
- What is Atea Pharmaceuticals, Inc.'s revenue?
- $351.4M over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Atea Pharmaceuticals, Inc.'s net income?
- -$165.3M over the twelve months to 2026-06-30.
- What is Atea Pharmaceuticals, Inc.'s free cash flow?
- -$152.1M over the twelve months to 2026-06-30.
- What are Atea Pharmaceuticals, Inc.'s diluted earnings per share?
- $-2.08 over the twelve months to 2026-06-30.
Every figure on this page comes from Atea Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.